A 55-year-old woman with long-standing type 2 diabetes and prior myocardial infarction has an HbA1c of 7.6% on metformin and basal insulin. Her eGFR is 55 mL/min/1.73 m². According to Diabetes Canada pharmacologic guidance, which additional antihyperglycaemic therapy is preferred to reduce cardiovascular risk?